Video Insights

Roundtable: Focus on Bispecifics in Myeloma
Karun Neupane, MDVideo Insights | September 22, 2023
Karun Neupane, MD, discusses why the meeting was a valuable experience for him as a first-time attendee.
View More
Sangeetha Venugopal, MDMyelofibrosis | September 20, 2023
Myelofibrosis Awareness Day is marked on September 20th each year.
Thomas Martin, MDVideo Insights | September 19, 2023
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
Sagar Lonial, MD, FACPVideo Insights | September 19, 2023
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
Loretta Nastoupil, MDVideo Insights | September 15, 2023
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
Swaminathan Iyer, MDVideo Insights | September 14, 2023
Swaminathan Iyer, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss advances in T-cell lymphoma.
Alessandra Ferrajoli, MDMeeting News | September 14, 2023
Alessandra Ferrajoli, MD, discusses her presentation on the topic during the Eleventh Annual Meeting of SOHO.
Mary Ann Anderson, MBBS, PhDMeeting News | September 13, 2023
Dr. Anderson spoke about her plenary session on the topic at the Eleventh Annual Meeting of SOHO.
Chadi Nabhan, MD, MBA, FACPMeeting News | September 10, 2023
Dr. Nath spoke transplant in patients with AML who are elderly and emphasized the need to include them in clinical trials.
Rami Komrokji, MDVideo Insights | September 10, 2023
Dr. Komrokji speaks about what might follow the recent FDA approval of luspatercept for certain patients with MDS.
Jorge Cortes, MDVideo Insights | September 10, 2023
Dr. Cortes speaks about the plenary session he delivered during the Eleventh Annual Meeting of SOHO.
Karun Neupane, MDVideo Insights | September 10, 2023
The single-center study was conducted to address gaps in knowledge surrounding minority-predominant populations of patients.
Chadi Nabhan, MD, MBA, FACPMeeting News | September 8, 2023
Dr. Platzbecker joins Chadi Nabhan, MD, MBA, FACP, to discuss MDS at the Eleventh Annual Meeting of SOHO.
Marina Konopleva, MD, PhDMeeting News | September 8, 2023
Dr. Konopleva explains the controversy and what she sees on the horizon for MRD in AML.
Guillermo Garcia-Manero, MDMeeting News | September 7, 2023
Guillermo Garcia-Manero, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss the COMMANDS trial at the SOHO Annual Meeting.
Tycel Phillips, MDVideo Insights | September 1, 2023
The meeting will be held September 6-9, 2023, in Houston, Texas.
Ajay Nooka, MD, FACPMyeloma | August 28, 2023
Ajay Nooka, MD, FACP, discusses the data behind the FDA accelerated approval of elranatamab.
Cecilia BrownMyeloma | August 21, 2023
Dr. Nooka, who served as an investigator on the MagnetisMM-3 trial, discusses the impact of the accelerated approval.
Shambavi Richard, MDMyeloma | July 17, 2023
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
Claudio Cerchione, MD, PhDMyeloma | July 5, 2023
Dr. Cerchione discusses the importance of ensuring adequate representation in multiple myeloma clinical trials.
Nico Gagelmann, MDMeeting News | June 28, 2023
Dr. Gagelmann outlines the challenges that he sees in Europe and across the globe for young researchers and clinicians.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panelists highlight key data presented at ASCO 2023.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
Leah SherwoodAcute Lymphoblastic Leukemia | June 26, 2023
The study showed that the infusion of obe-cel resulted in very low rates of Grade 3 or higher CRS and ICANS.
Leah SherwoodMyeloma | June 23, 2023
In this video interview from EHA, Dr, Munshi shares the close-out efficacy and safety results from CARTITUDE-1.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 23, 2023
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 23, 2023
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 22, 2023
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
Nico Gagelmann, MDMeeting News | June 22, 2023
Dr. Gagelmann outlines key highlights of the session, his presentation and what he hopes attendees learned from the session.
Marco Ruella, MDMeeting News | June 21, 2023
A specific subset of antibiotics "were particularly bad" for the microbiome and were associated with poor survival.
Cecilia BrownMeeting News | June 14, 2023
Dr. Kuykendall and colleagues presented their findings during the 2023 European Hematology Association Congress.
Cecilia BrownVideo Insights | June 13, 2023
Dr. Winer discusses emavusertib, an orally bioavailable, reversible inhibitor of IRAK4.
Chadi Nabhan, MD, MBA, FACPMeeting News | June 13, 2023
Dr. Nabhan, who hosts The HemOnc Pulse, discusses the podcast and what he hopes listeners gain from it at ASCO 2023.
Leah SherwoodVideo Insights | June 13, 2023
Dr. Krecak presented the research during the 2023 EHA Congress.
Cecilia BrownMeeting News | June 13, 2023
Dr. Venugopal, who was not involved in the study, discusses the results and implications of the phase III trial.
Chadi Nabhan, MD, MBA, FACPVideo Insights | June 12, 2023
Dr. Nabhan also speaks about his next book, which is expected to be released in fall 2024.
Thomas Martin, MDMeeting News | June 12, 2023
Dr. Martin discusses key updates in multiple myeloma from ASCO, EHA, and the IMWG meetings.
Leah SherwoodMeeting News | June 12, 2023
The study evaluated imetelstat versus placebo in patients with lower-risk MDS who were highly transfusion dependent.
Rachel Thijssen, PhDMeeting News | June 9, 2023
Dr. Thijssen served as chair for the Young EHA session on senescence, aging, and cell death.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 9, 2023
The panel considers triplet versus quadruplet therapy for myeloma induction.
Guillermo Garcia-Manero, MDVideo Insights | June 9, 2023
Dr. Garcia-Manero presented results from the phase III COMMANDS trial during the 2023 ASCO Meeting.
Cecilia BrownMyeloma | June 8, 2023
The response rates seen with talquetamab in the trial were "very impressive," Dr. Schinke said.
Cecilia BrownMyeloproliferative Neoplasms | June 8, 2023
The study indirectly compared safety outcomes from phase II and phase III trials of momelotinib and fedratinib.
Cecilia BrownMyeloma | June 7, 2023
The study evaluated teclistamab in patients with relapsed or refractory multiple myeloma.
Chadi Nabhan, MD, MBA, FACPMeeting News | June 7, 2023
Dr. Rutherford and colleagues hypothesized there would be no impact on PFS when imaging was performed less frequently.
Prithviraj Bose, MDMyelofibrosis | June 7, 2023
Prithviraj Bose, MD, and colleagues presented results of the study during the 2023 ASCO Annual Meeting.
Cecilia BrownChronic Lymphocytic Leukemia | June 7, 2023
The real-world analysis of racial disparities in CLL accounted for the treatment that patients received.
Advertisement
Advertisement

Knowledge Hubs

Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Advertisement
Advertisement
Editorial Board